A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Interleukin-2 (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 Apr 2016 Status changed from active, no longer recruiting to completed according to results published in the Blood.
- 12 Apr 2016 Results published in the Blood